← Back to Search

Gastrointestinal Hormone

Treatment for Short Bowel Syndrome

N/A
Waitlist Available
Research Sponsored by Shire
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 years
Awards & highlights

Summary

This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants with SBS. SBS participants treated and not treated with teduglutide will be enrolled.

Eligible Conditions
  • Short Bowel Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Occurrence of Colorectal Cancer in Short Bowel Syndrome (SBS) Participants With a Remnant Colon Currently Being Treated With or Ever Having Been Treated With Teduglutide
Secondary outcome measures
Actual Change in the Number of Days per Week on Parenteral Support (PS)
Actual Volume Change in Parenteral Support (PS)
Occurrence of Allergic/Hypersensitivity Reaction to Teduglutide
+10 more

Find a Location

Who is running the clinical trial?

ShireLead Sponsor
456 Previous Clinical Trials
95,478 Total Patients Enrolled
16 Trials studying Short Bowel Syndrome
1,186 Patients Enrolled for Short Bowel Syndrome
Takeda Development Center Americas, Inc.Industry Sponsor
56 Previous Clinical Trials
10,240 Total Patients Enrolled
Study DirectorStudy DirectorShire
1,252 Previous Clinical Trials
502,579 Total Patients Enrolled
22 Trials studying Short Bowel Syndrome
1,603 Patients Enrolled for Short Bowel Syndrome
~820 spots leftby Apr 2033